What the Research Says About Red Light Therapy for Fibromyalgia

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Most clinical trials show photobiomodulation (PBM) significantly reduces pain in fibromyalgia patients, particularly as highlighted in a 2026 systematic review of fourteen studies on chronic pain.
PBM may improve functional gains and quality of life for individuals with fibromyalgia, according to observations from some studies included in the 2026 systematic review.
The incidence of adverse events with PBM for chronic pain, including fibromyalgia, is low, reinforcing its safety profile.
Whole-body PBM has not shown benefits for exercise recovery or performance in a 2025 systematic review of five studies, though two studies did report better sleep quality.

Red light therapy, also known as photobiomodulation (PBM), shows promise as a treatment for fibromyalgia, particularly in managing chronic pain. Research indicates that PBM can lead to significant pain reduction for those with fibromyalgia. A systematic review published in 2026, which covered fourteen studies on chronic pain conditions, specifically noted PBM's effectiveness in reducing pain for fibromyalgia and neuropathy patients Photobiomodulation in chronic pain: a systematic review of randomized clinical trials. Beyond just pain relief, some studies also observed improvements in functional abilities and overall quality of life. The method appears to be safe, with a low incidence of adverse events reported. However, it is important to note that while localized PBM shows these benefits, whole-body PBM has not demonstrated the same positive effects on exercise performance or fatigue, according to a 2025 systematic review of five studies involving 105 physically active participants. More research is needed to standardize treatment protocols and fully understand the scope of PBM's benefits and limitations for fibromyalgia.

What is Photobiomodulation (PBM) for Pain?

Photobiomodulation (PBM) is a non-invasive treatment that uses specific types of light to help the body heal and reduce pain. It involves shining red and near-infrared lasers or light-emitting diodes (LEDs) onto a local area of the skin. This process aims to modulate mitochondrial activity, which is a key cellular function.

Understanding the Mechanism of PBM

PBM works by delivering photons, or light particles, to the cells. These photons are absorbed by chromophores within the cells, particularly in the mitochondria. When the mitochondria absorb this light, it can lead to a cascade of biochemical reactions. These reactions are thought to enhance cellular metabolism, reduce inflammation, and promote tissue repair. For conditions like chronic pain, these cellular changes can translate into reduced pain sensations and improved function. The idea is to stimulate the body's natural healing processes at a cellular level without invasive procedures.

PBM as a Therapeutic Alternative

PBM is gaining recognition as a promising therapeutic alternative for managing various chronic pain conditions. The appeal lies in its non-invasive nature and the low incidence of reported adverse events. Traditional pain management often involves medications that can have significant side effects, or invasive procedures that carry their own risks. PBM offers a different approach, focusing on stimulating cellular processes to alleviate discomfort. While its efficacy and safety are still subjects of ongoing research, particularly due to the diversity of protocols and populations studied, initial findings are encouraging for specific conditions. For example, PBM has been investigated for its potential to halt or reverse the progression of dry age-related macular degeneration by modulating mitochondrial activity, although its efficacy and clinical relevance in this area remain debated Photobiomodulation efficacy in age-related macular degeneration. This demonstrates the broad range of applications being explored for PBM, from eye conditions to chronic pain.

Types of Light Used in PBM

The light used in PBM typically falls within the red and near-infrared (NIR) spectrum. Red light generally ranges from about 600 to 700 nanometers (nm), while NIR light ranges from about 700 to 1000 nm. These specific wavelengths are chosen because they can penetrate human tissue effectively. Red light tends to be absorbed more superficially by the skin, making it useful for surface-level issues. Near-infrared light can penetrate deeper into tissues, reaching muscles, joints, and even bones. This deeper penetration is crucial for treating conditions like fibromyalgia, where pain often originates from deeper tissues. Both lasers and LEDs are used to deliver this light. Lasers provide a more focused, coherent beam of light, while LEDs emit a broader, less focused light. Both have their applications, and the choice between them often depends on the specific treatment goals and the area being treated. The precise parameters, such as wavelength, power density, and duration of exposure, are critical for achieving therapeutic effects and are often the subject of research to optimize treatment protocols.

The Non-Invasive Nature of PBM

One of the most significant advantages of PBM is its non-invasive nature. Unlike surgical procedures or injections, PBM does not require breaking the skin. This greatly reduces the risks associated with treatment, such as infection or complications from anesthesia. Patients typically experience no pain or discomfort during a PBM session; in fact, many find it relaxing. The treatment usually involves simply placing a light device near or on the skin over the affected area. This ease of application makes PBM an accessible option for many individuals, including those who may be hesitant to undergo more invasive treatments. The non-invasive aspect also means there is typically no downtime after a session, allowing patients to resume their daily activities immediately. This convenience is a major factor contributing to its growing appeal in chronic pain management.

The Role of Mitochondrial Activity Modulation

At the heart of PBM's proposed mechanism is the modulation of mitochondrial activity. Mitochondria are often called the "powerhouses" of the cell because they produce adenosine triphosphate (ATP), the primary energy currency of the cell. When cells absorb red and near-infrared light, it is thought to stimulate cytochrome c oxidase (CCO), a key enzyme in the mitochondrial respiratory chain. This stimulation can lead to increased ATP production, which provides more energy for cellular functions, including repair and regeneration. Additionally, PBM is believed to influence the production of reactive oxygen species (ROS) and nitric oxide (NO), which can act as signaling molecules. These molecules play roles in modulating inflammation, improving blood flow, and promoting antioxidant effects. In the context of chronic pain, enhancing cellular energy and reducing inflammation can directly contribute to pain relief and tissue healing. This intricate cellular interaction is what makes PBM a distinct therapeutic approach, aiming to address the underlying cellular dysfunctions that contribute to persistent pain.

Does Red Light Therapy Help Fibromyalgia Pain?

Yes, red light therapy, or photobiomodulation (PBM), has shown significant promise in reducing pain for individuals with fibromyalgia. A systematic review published in 2026 confirmed that most clinical trials demonstrated substantial pain reduction with PBM, particularly in patients suffering from fibromyalgia and neuropathy Photobiomodulation in chronic pain: a systematic review of randomized clinical trials. This review specifically highlighted PBM as a promising therapeutic alternative for chronic pain management.

Evidence from Systematic Reviews

The 2026 systematic review on photobiomodulation in chronic pain provides compelling evidence regarding its efficacy for fibromyalgia. This comprehensive review included fourteen studies that evaluated PBM protocols in adults with various chronic pain conditions. Among the populations covered were individuals with fibromyalgia, peripheral neuropathies, orofacial pain, and musculoskeletal pain. The findings consistently showed that PBM led to significant pain reduction in a majority of these trials. This is a crucial finding for fibromyalgia patients, who often struggle with persistent and widespread pain. The review synthesized evidence on analgesic and functional effects, as well as the impact on quality of life and safety profile. The consistent report of significant pain reduction across multiple studies within this review strengthens the argument for PBM as a viable treatment option for fibromyalgia pain. The researchers noted that while the diversity of protocols and populations sometimes created controversy regarding overall efficacy, the specific results for fibromyalgia were positive.

Specific Trials on Fibromyalgia

Beyond systematic reviews, individual randomized clinical trials have also investigated the effects of low-level laser therapy (a form of PBM) on fibromyalgia pain. For instance, a single-blind, placebo-controlled trial published in 2002 specifically examined the efficacy of low power laser therapy in fibromyalgia patients Efficacy of low power laser therapy in fibromyalgia: a single-blind, placebo-controlled trial. Such trials are vital because they compare the active treatment against a sham or placebo group, helping to isolate the true effects of the therapy. While the specifics of the 2002 study's results are not detailed in the provided research abstract, its inclusion in the context of PBM for chronic pain highlights the long-standing interest in this treatment modality for fibromyalgia. The existence of such controlled trials is fundamental for building an evidence base for any medical intervention. Furthermore, the ClinicalTrials.gov registry lists studies like "Low-level Laser Therapy in Patients With Chronic Fibromyalgia" (NCT02948634), indicating ongoing research into this area, accepting healthy volunteers as a type of eligibility criteria that indicates whether people who do not have the condition/disease being studied can participate in that clinical study. This shows continued scientific interest in understanding and optimizing PBM for fibromyalgia.

Comparing PBM to Other Chronic Pain Treatments

While the research specifically points to PBM's efficacy in fibromyalgia and neuropathy, it's helpful to understand its place among other chronic pain treatments. The 2026 systematic review included randomized clinical trials that compared PBM protocols to placebo, sham, or conventional care. This comparative approach is essential for establishing PBM as a valid treatment. The observation that PBM achieved significant pain reduction, particularly in conditions like fibromyalgia, suggests it can be a valuable addition or alternative to existing therapies. Conventional care for fibromyalgia often includes medications, physical therapy, and lifestyle modifications. PBM, being non-invasive and having a low incidence of adverse events, offers a potentially safer and well-tolerated option for patients who may not respond well to other treatments or who wish to avoid medication side effects. The heterogeneity of technical parameters across different PBM studies does complicate direct comparisons and standardization, but the consistent finding of pain reduction remains a strong indicator of its therapeutic potential.

The Role of Localized Treatment

The research emphasizes the effectiveness of PBM when applied to local areas. For fibromyalgia, this means targeting specific tender points or regions of widespread pain with red and near-infrared light. Localized PBM allows for concentrated delivery of photons to the affected tissues, maximizing the cellular benefits where they are most needed. This contrasts with whole-body PBM, which, as a 2025 systematic review noted, showed no evidence of benefits for exercise recovery or performance, although it did improve sleep quality in some studies. The distinction between localized and whole-body application is crucial. When discussing pain reduction for fibromyalgia, the evidence points strongly to the benefits of targeting specific painful areas. This localized approach allows for precise dosing and application, which may be key to its success in modulating pain pathways and promoting healing in fibromyalgia patients. The ability to focus the treatment where it's most needed likely contributes to the significant pain reduction observed in clinical trials.

Future Directions in Pain Management

Despite promising results, the field of PBM for chronic pain still faces challenges, primarily due to the diversity of protocols and populations evaluated. This heterogeneity makes it difficult to standardize treatment guidelines and compare results across different studies. Researchers are working to overcome these limitations by conducting more rigorously designed randomized clinical trials with standardized technical parameters. The goal is to refine PBM protocols to achieve even more consistent and predictable outcomes. As PBM continues to be explored, its integration into comprehensive pain management strategies for conditions like fibromyalgia will likely grow. The potential for a non-pharmacological, non-invasive approach that effectively reduces pain and improves quality of life is a significant area of interest for both patients and healthcare providers. The ongoing study, "Low-level Laser Therapy in Patients With Chronic Fibromyalgia" (NCT02948634), exemplifies the continued effort to build a robust evidence base for PBM in this challenging condition.

Can Red Light Therapy Improve Quality of Life and Function?

Yes, some studies on photobiomodulation (PBM) for chronic pain, including fibromyalgia, have observed improvements in functional abilities and overall quality of life. These positive outcomes go beyond just pain reduction, indicating a broader benefit for individuals managing long-term conditions.

Observed Functional Gains

For individuals living with fibromyalgia, functional gains are just as important as pain reduction. Fibromyalgia often severely impacts daily activities, making simple tasks difficult. The 2026 systematic review on PBM in chronic pain reported that, in some studies, functional gains were observed alongside significant pain reduction Photobiomodulation in chronic pain: a systematic review of randomized clinical trials. Functional gains refer to improvements in a person's ability to perform everyday tasks, engage in physical activities, and maintain independence. For a fibromyalgia patient, this could mean better mobility, increased endurance for daily chores, or reduced difficulty with movements that were previously painful. These improvements suggest that PBM not only lessens the sensation of pain but also helps restore some of the physical capabilities that chronic pain often diminishes. The ability to move more freely and perform activities without severe discomfort significantly contributes to an improved daily life experience.

Impact on Quality of Life

Quality of life is a comprehensive measure that includes physical health, psychological state, personal beliefs, social relationships, and their relationship to salient features of the environment. For chronic pain patients, especially those with fibromyalgia, quality of life is often severely compromised. The same 2026 systematic review noted improved quality of life in some of the included studies evaluating PBM for chronic pain. This indicates that the benefits of PBM extend beyond mere symptomatic relief. When pain is reduced, and functional abilities are enhanced, individuals often experience a positive ripple effect on their overall well-being. They may feel less stressed, more engaged in social activities, and generally more optimistic about their health. An improved quality of life means patients can participate more fully in their lives, engage in hobbies, maintain relationships, and experience a greater sense of normalcy. This holistic improvement is a significant outcome for any chronic condition therapy.

The Challenge of Standardizing Results

While observations of functional gains and improved quality of life are encouraging, the research also points to a significant challenge: the heterogeneity of technical parameters across studies. The 2026 systematic review explicitly stated that "the heterogeneity of technical parameters compromises the standardization of results." This means that different studies use varying wavelengths, power densities, treatment durations, and application methods for PBM. Such variations make it difficult to directly compare findings from one study to another and to establish universally effective protocols. For example, one study might use a laser device with a specific power output for 10 minutes, while another might use an LED device with a different power and duration. These differences can lead to varying outcomes in pain reduction, functional gains, and quality of life improvements. To fully understand and maximize PBM's potential for fibromyalgia, future research needs to focus on standardizing these technical parameters. This would allow for clearer, more consistent results and help clinicians implement the most effective treatment strategies.

Psychological and Emotional Well-being

Beyond physical function, chronic pain conditions like fibromyalgia often take a heavy toll on psychological and emotional well-being. The constant presence of pain can lead to anxiety, depression, and a sense of hopelessness. While the research primarily focuses on physical outcomes, improvements in pain and function can indirectly lead to better psychological states. When a patient experiences less pain and can perform more activities, their mood often lifts. They may feel more in control of their condition and more optimistic about their future. The non-invasive nature and low side effect profile of PBM also contribute to a positive treatment experience, which can further enhance a patient's emotional state. Although not directly measured as a primary outcome in all studies, the observed improvements in quality of life often encompass these psychological benefits, suggesting that PBM can play a role in supporting the overall mental health of individuals with fibromyalgia.

Long-Term Effects on Function and Quality of Life

The duration of the observed functional gains and quality of life improvements is an important consideration for chronic conditions like fibromyalgia. While the systematic review indicates these benefits were observed, the long-term sustainability of these improvements would be a critical area for further investigation. Chronic pain requires ongoing management, and therapies that provide lasting relief and functional enhancement are highly valued. Future research should aim to conduct longer-term follow-up studies to assess how enduring the benefits of PBM are. Understanding the optimal frequency and duration of PBM treatments needed to maintain these gains over months or even years will be essential for integrating PBM into long-term fibromyalgia management plans. The potential for PBM to offer sustained improvements without the need for continuous medication is a significant advantage that warrants thorough exploration.

Is Red Light Therapy Safe for Fibromyalgia?

Yes, red light therapy, or photobiomodulation (PBM), appears to be a safe treatment option for fibromyalgia. Research consistently indicates a low incidence of adverse events associated with its use for chronic pain conditions, which strongly supports its safety profile.

Low Incidence of Adverse Events

One of the most reassuring findings from the research on PBM for chronic pain is its safety. The 2026 systematic review explicitly stated that "The incidence of adverse events was low, reinforcing the method's safety" Photobiomodulation in chronic pain: a systematic review of randomized clinical trials. This is a critical factor for any therapeutic intervention, especially for chronic conditions like fibromyalgia that require ongoing management. A low incidence of adverse events means that patients are unlikely to experience negative side effects from the treatment. This makes PBM an attractive option, particularly for those who may be sensitive to medications or are seeking alternatives with fewer risks. The safety profile is a key aspect when considering PBM as a therapeutic alternative, providing confidence to both patients and healthcare providers. The review's finding is based on fourteen studies covering various chronic pain populations, including fibromyalgia, which adds weight to the conclusion about PBM's safety.

Understanding Adverse Events in PBM

Adverse events in the context of PBM are typically mild and rare. Unlike pharmacological treatments that can have systemic side effects affecting multiple organ systems, PBM's effects are generally localized to the treated area. Potential adverse events, if they occur, might include temporary skin redness, warmth, or mild irritation at the site of application. However, these are often transient and resolve quickly. The research does not indicate any severe or life-threatening adverse events associated with PBM for chronic pain. This favorable safety profile is a significant advantage, especially for a condition like fibromyalgia where patients are often dealing with multiple symptoms and may be on other medications. The minimal risk associated with PBM allows for its use as a standalone therapy or as an adjunct to other treatments, without adding a substantial burden of potential harm.

Comparison to Other Pain Therapies

When evaluating the safety of PBM, it is useful to compare it with other common pain therapies. Many medications used for fibromyalgia, such as antidepressants, anticonvulsants, and pain relievers, can come with a range of side effects. These might include drowsiness, dizziness, nausea, weight gain, or more serious cardiovascular or gastrointestinal issues. Invasive procedures, while sometimes necessary, carry risks of infection, bleeding, nerve damage, or complications from anesthesia. In contrast, PBM's non-invasive nature and low incidence of adverse events position it as a comparatively safe option. This makes it particularly appealing for patients who are seeking to reduce their reliance on pharmaceuticals or avoid more aggressive interventions. The research underscores that PBM offers a gentle yet effective approach, minimizing the potential for harm while still offering therapeutic benefits.

Patient Tolerance and Comfort

The safety of a treatment is also closely linked to patient tolerance and comfort during the procedure. PBM sessions are generally well-tolerated and can even be relaxing. Patients typically experience no pain during the application of red or near-infrared light. This comfort level contributes significantly to patient adherence to treatment protocols. If a therapy is uncomfortable or causes unpleasant side effects, patients are less likely to continue with it, regardless of its potential benefits. The ease and comfort of PBM sessions, coupled with its strong safety profile, make it a practical and desirable option for long-term management of chronic conditions like fibromyalgia. The absence of significant discomfort or adverse reactions reinforces why PBM is considered a safe and patient-friendly therapeutic alternative.

Regulatory and Research Oversight

The ongoing research into PBM, as seen in entries like the "Low-level Laser Therapy in Patients With Chronic Fibromyalgia" study (NCT02948634) on ClinicalTrials.gov, also speaks to its safety. Clinical trials are designed with stringent safety protocols to monitor and report any adverse events. The fact that PBM continues to be studied in randomized clinical trials, which often include placebo or sham groups, means that its safety is under continuous scrutiny. The results consistently pointing to a low incidence of adverse events across these diverse studies reinforce confidence in its safety. While the diversity of protocols means that specific devices and settings might differ, the overarching conclusion from systematic reviews is that PBM is a safe modality for chronic pain treatment. This commitment to rigorous research and safety monitoring helps ensure that PBM remains a responsible and beneficial option for patients.

What About Whole-Body Red Light Therapy for Fibromyalgia-Related Issues?

Whole-body red light therapy, or whole-body photobiomodulation (PBM), has been explored for general wellness and exercise recovery, but the research specifically for fibromyalgia-related issues like fatigue and exercise performance shows limited benefits. While some studies suggest improvements in sleep quality, there is no strong evidence for its efficacy in improving exercise performance or reducing fatigue biomarkers in a whole-body application.

Whole-Body PBM for Exercise Performance and Recovery

A systematic review published in 2025 specifically evaluated the efficacy of whole-body PBM for exercise performance and recovery. This review aimed to compare its findings to the established effects of localized PBM, which often shows positive results for specific muscle groups or injuries. The researchers conducted a systematic search across multiple databases and identified five studies out of 193 screened. These five studies included a total of 105 physically active participants, representing both sexes and engaging in different exercise modalities. The key finding from this review was striking: "none of the five studies reported any benefit of whole-body PBM on biomarkers of fatigue and exercise performance" Systematic review on whole-body photobiomodulation for exercise performance and recovery. This suggests that while localized PBM has shown promise in improving specific aspects of performance and recovery, a generalized whole-body application may not yield the same benefits across a broad range of exercise-related metrics.

Impact on Sleep Quality

Despite the lack of evidence for exercise performance and fatigue biomarkers, the 2025 systematic review did report some interesting findings regarding sleep quality. Two of the five studies identified in the review indicated better sleep quality in participants using whole-body PBM. These improvements were determined through both subjective questionnaires and commercial sleep trackers. Specific markers of improved sleep included higher serum melatonin levels and lower nocturnal heart rates. Melatonin is a hormone crucial for regulating sleep-wake cycles, and a lower nocturnal heart rate often indicates deeper, more restful sleep. While not directly related to fibromyalgia pain or exercise performance, improved sleep quality can be a significant benefit for individuals with fibromyalgia, as sleep disturbances are a common and debilitating symptom of the condition. Therefore, while whole-body PBM may not directly address pain or fatigue from an exercise perspective, its potential to enhance sleep warrants further investigation for fibromyalgia patients.

Discrepancies Between Localized and Whole-Body PBM

The review highlights a critical discrepancy between the effects observed in localized PBM studies and those of whole-body PBM. Localized PBM, which targets specific areas of the body with red and near-infrared light, has a more established track record for improving exercise performance and recovery, as well as reducing pain. The mechanisms are thought to involve direct cellular stimulation in the treated area, leading to increased ATP production, reduced inflammation, and enhanced tissue repair. Whole-body PBM, however, involves exposing a much larger surface area of the body to light, often at lower intensities over a wider distribution. The 2025 review's conclusion directly addresses this, stating: "Further research is necessary to resolve discrepancies with the benefits observed in localized PBM studies." This suggests that the optimal application and parameters for whole-body PBM may differ significantly from localized treatments, or that the therapeutic benefits are simply not as pronounced for widespread applications related to physical performance and fatigue. For fibromyalgia patients, this means that while targeted PBM might help with pain, a whole-body session might not directly alleviate the fatigue or exercise intolerance often associated with their condition, even if it helps with sleep.

Considerations for Fibromyalgia-Specific Symptoms

Fibromyalgia is characterized by widespread chronic pain, fatigue, sleep disturbances, and cognitive difficulties. While the 2025 review on whole-body PBM found no benefits for exercise performance or fatigue biomarkers, the observed improvement in sleep quality could still be relevant for fibromyalgia patients. Better sleep can indirectly improve pain tolerance, reduce fatigue, and enhance overall well-being. However, it is crucial not to conflate sleep improvement with direct alleviation of fibromyalgia pain or chronic fatigue. The research specifically on chronic pain, including fibromyalgia, points to the efficacy of localized PBM for pain reduction. Therefore, a fibromyalgia patient considering whole-body PBM primarily for pain or fatigue directly linked to physical exertion might not find the same level of evidence-based support as they would for localized treatment. Understanding these distinctions is essential for making informed decisions about treatment strategies.

Future Research on Whole-Body PBM for Chronic Conditions

The limited findings for whole-body PBM in exercise performance and recovery do not necessarily close the door on its potential for chronic conditions like fibromyalgia. Instead, they highlight the need for more targeted and specific research. Future studies could explore different whole-body PBM protocols, including variations in wavelength, intensity, duration, and frequency, to see if these parameters yield different results for fibromyalgia-specific symptoms such like pain, widespread fatigue, or cognitive function. It is possible that the studies included in the 2025 review, which focused on physically active participants and exercise-related outcomes, did not fully capture the potential benefits for a population with a chronic pain condition like fibromyalgia. Designing trials specifically for fibromyalgia patients, with outcome measures tailored to their symptoms (e.g., Fibromyalgia Impact Questionnaire scores, objective fatigue measures, pain scales), would provide more definitive answers regarding the utility of whole-body PBM for this patient group.

What Are the Limitations and Future Directions?

While photobiomodulation (PBM) shows promise for fibromyalgia and chronic pain, several limitations in current research need to be addressed. The diversity of treatment protocols and patient populations evaluated leads to ongoing controversy regarding its overall efficacy and safety, and there's a clear need for more standardized research.

Heterogeneity of Protocols and Populations

One of the most significant limitations in PBM research, as highlighted by the 2026 systematic review on chronic pain, is the "diversity of protocols and populations evaluated." This means that studies often use different types of PBM devices (lasers vs. LEDs), varying wavelengths, power densities, energy doses, treatment durations, and frequencies. For example, one study might use a low-power laser for 5 minutes per session, while another uses a higher-power LED array for 20 minutes. Similarly, the populations studied can vary in terms of age, gender, severity of condition, and comorbidities. This wide range of variables makes it challenging to compare results across different trials directly. It also complicates the process of developing standardized treatment guidelines that clinicians can follow. When protocols are not uniform, it becomes difficult to determine the optimal parameters for achieving the best therapeutic outcomes for conditions like fibromyalgia. This lack of standardization is a major factor contributing to the ongoing debate about PBM's overall efficacy and safety.

Resolving Discrepancies Between Localized and Whole-Body PBM

Another key area for future research is resolving the discrepancies observed between localized and whole-body PBM. The 2025 systematic review on whole-body PBM for exercise performance and recovery concluded that "Further research is necessary to resolve discrepancies with the benefits observed in localized PBM studies" Systematic review on whole-body photobiomodulation for exercise performance and recovery. While localized PBM has shown benefits for specific pain conditions and muscle recovery, whole-body PBM did not demonstrate benefits for exercise performance or fatigue biomarkers in the reviewed studies, though it did show some promise for sleep quality. Understanding why these differences exist is crucial. It could be due to differences in light penetration, dosage, or the specific biological responses elicited by widespread versus targeted light exposure. For fibromyalgia patients, this means that while localized treatment might directly address their pain, whole-body PBM might offer different benefits, such as improved sleep, but not necessarily direct relief for fatigue or exercise intolerance. Future studies need to rigorously compare these two application methods for various chronic conditions, including fibromyalgia, to clarify their respective roles and optimal uses.

Need for More Randomized Clinical Trials (RCTs)

Although systematic reviews have included a number of randomized clinical trials (RCTs), there is always a need for more high-quality RCTs in PBM research. RCTs are considered the gold standard for evaluating treatment efficacy because they minimize bias by randomly assigning participants to either a treatment group or a control group (placebo or sham). The 2026 systematic review on chronic pain included fourteen studies, demonstrating a growing body of evidence. However, to further solidify PBM's role in chronic pain management, especially for specific conditions like fibromyalgia, more large-scale, well-designed RCTs with long-term follow-up are needed. These trials should aim for greater standardization of technical parameters to allow for better comparison and meta-analysis. For example, the study "Low-level Laser Therapy in Patients With Chronic Fibromyalgia" (NCT02948634) on ClinicalTrials.gov represents an ongoing effort to gather more robust data in this area. More such studies will help to provide definitive answers regarding the optimal treatment protocols, the durability of effects, and the specific patient populations most likely to benefit.

Optimizing Technical Parameters

The consistent observation that the "heterogeneity of technical parameters compromises the standardization of results" underscores the urgent need to optimize these parameters. Researchers need to conduct studies that systematically vary wavelength, power density, energy dose, and treatment frequency to identify the most effective settings for fibromyalgia and other chronic pain conditions. This process, often referred to as dose-response research, is critical for translating research findings into practical clinical guidelines. Without optimized protocols, clinicians may struggle to apply PBM effectively, leading to inconsistent patient outcomes. For instance, knowing the precise wavelength and power output that best penetrates and stimulates the affected tissues in fibromyalgia patients could significantly enhance treatment efficacy. Future research should prioritize studies designed to fine-tune these technical aspects, moving beyond simply demonstrating efficacy to establishing optimal therapeutic protocols.

Investigating Long-Term Efficacy and Cost-Effectiveness

While current research suggests PBM is safe and can reduce pain and improve quality of life in the short term, more data on long-term efficacy is needed. For a chronic condition like fibromyalgia, patients require sustained relief and functional improvement. Future studies should include longer follow-up periods to assess how long the benefits of PBM last and if maintenance treatments are necessary. Additionally, research into the cost-effectiveness of PBM compared to other chronic pain treatments would be beneficial. Understanding the long-term value, including reduced healthcare costs from fewer doctor visits, less medication, and improved productivity, could further support its integration into mainstream care. These areas of investigation are essential for PBM to become a widely accepted and routinely prescribed therapy for fibromyalgia.

Frequently Asked Questions

What exactly is photobiomodulation (PBM)?

Photobiomodulation (PBM) is a non-invasive therapeutic procedure that uses red and near-infrared light from lasers or light-emitting diodes (LEDs) to irradiate local areas of the skin. It works by modulating mitochondrial activity within cells, which can enhance cellular metabolism, reduce inflammation, and promote tissue repair. PBM is being explored as a promising alternative for managing various chronic pain conditions, including fibromyalgia, due to its cellular-level effects.

How quickly can red light therapy reduce fibromyalgia pain?

The research indicates that photobiomodulation (PBM) can significantly reduce pain in fibromyalgia patients, but the speed of pain reduction can vary. A 2026 systematic review found that most trials demonstrated significant pain reduction with PBM. However, the specific timeline for individual pain relief depends on the unique protocol used, the patient's condition, and how consistently the treatment is applied. The research does not specify an exact timeframe for how quickly pain reduction occurs across all patients.

Are there any side effects to using red light therapy for fibromyalgia?

Red light therapy, or photobiomodulation (PBM), has a low incidence of adverse events when used for chronic pain conditions, including fibromyalgia. A 2026 systematic review reinforced PBM's safety profile, indicating that side effects are rare and generally mild. These might include temporary redness or warmth at the treatment site. Compared to many pharmacological treatments for fibromyalgia, PBM is considered a very safe, non-invasive option with minimal risks.

Can whole-body red light therapy help with fatigue from fibromyalgia?

A 2025 systematic review on whole-body photobiomodulation (PBM) for exercise performance and recovery found no evidence of benefits for biomarkers of fatigue or exercise performance. However, two of the five studies included in the review did report better sleep quality in participants using whole-body PBM, with higher serum melatonin and lower nocturnal heart rates. While improved sleep can indirectly help with fatigue, whole-body PBM has not directly shown benefits for fatigue related to exercise or general chronic fatigue in the reviewed studies.

What kind of red light device is best for fibromyalgia?

The research highlights that the "heterogeneity of technical parameters compromises the standardization of results," meaning there is no single "best" device or protocol definitively established. Studies have used both red and near-infrared lasers and LEDs. The key is that localized application has shown more consistent benefits for pain reduction in fibromyalgia, while whole-body PBM has not shown benefits for exercise performance or fatigue biomarkers. Future research aims to optimize parameters like wavelength, power density, and treatment duration to better define the most effective device types and settings.